DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Clinical trials for DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill targets virus-driven lymphoma in early trial
Disease control Recruiting nowThis early-phase study tests an experimental daily pill, VK-2019, in 30 adults with a rare type of lymphoma (DLBCL) that is linked to the Epstein-Barr virus and has not responded to at least two prior treatments. The main goal is to find the safest dose by giving three different …
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Phase: PHASE1 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated May 26, 2026 05:44 UTC
-
New Dual-Targeting CAR t therapy aims to outperform standard treatment for blood cancer
Disease control Recruiting nowThis Phase 3 trial tests a new CAR T-cell therapy called ronde-cel, which targets two proteins (CD19 and CD20) on lymphoma cells, against the standard single-target CAR T therapy. The study involves 400 adults with large B-cell lymphoma that has returned or not responded after in…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Phase: PHASE3 • Sponsor: Lyell Immunopharma, Inc. • Aim: Disease control
Last updated May 26, 2026 05:39 UTC
-
New combo aims to salvage CAR t failures in lymphoma
Disease control Recruiting nowThis early-stage trial tests a combination of two drugs (CC-99282 and rituximab) in people with certain types of non-Hodgkin lymphoma whose cancer did not respond well to CAR T-cell therapy. The goal is to find the safest dose and see if the combo can help control the disease. Ab…
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Phase: PHASE1 • Sponsor: Nathan Denlinger • Aim: Disease control
Last updated May 26, 2026 05:37 UTC
-
New CAR T-Cell therapy targets tough blood cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called GF-CART01 for adults aged 18-70 with B-cell blood cancers (like certain lymphomas) that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to target two markers (CD20 …
Matched conditions: DIFFUSE LARGE B CELL LYMPHOMA REFRACTORY
Phase: PHASE1 • Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:35 UTC